Finally, it is well known that marijuana is an addictive substance. While it may not be more harmful than alcohol, it is a drug that causes intoxication, impaired judgment, and changes in brain chemistry and structure that impact the rest of your life.
Because the effects on IOP last only a few hours, medical marijuana does not help to maintain stable low eye pressure, which is necessary to reduce damage to the optic nerve.
The Science of Marijuana’s Impact on Glaucoma
Unfortunately, these newer methods of medical marijuana use do not work to lower intraocular pressure. A study found that eye drops containing THC did not lower intraocular pressure at all. Another study found that smoking marijuana lowered intraocular pressure, and the amount of cannabis ingested would lower IOP in measurable ways, but ingesting more cannabis would not lead to effects that lasted longer. The body still metabolized THC’s peak effects in three to four hours.
Eye Doctors Understand the Best Course of Glaucoma Treatment
Additionally, marijuana has been associated with eye problems, including:
Purpose: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetrahydrocannabinol (Delta-9-THC) and cannabidiol (CBD).
Results: Two hours after sublingual administration of 5 mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P=0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P=0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration.
Patients and methods: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM of 5 mg Delta-9-THC, 20 mg CBD, 40 mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects.
Conclusions: A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40 mg CBD produced a transient increase IOP rise.